Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 2No longer available 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Conditions

Breast Neoplasms 48Neoplasm Metastasis 11Hereditary Sensory and Autonomic Neuropathies 7Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Ovarian Neoplasms 5Neoplasms 5Triple Negative Breast Neoplasms 3Multiple Endocrine Neoplasia Type 1 3Lymphangioma 3Hyperglycemia 3Head and Neck Neoplasms 3Pancreatic Neoplasms 2Melanoma 2Lymphatic Abnormalities 2Lymphangioma, Cystic 2Head and Neck Squamous Cell Cancer 2Endometrial Neoplasms 2Colorectal Neoplasms 2Advanced Breast Cancer 2Vascular Malformations 1Uveal Melanoma 1Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein 1Stomach Neoplasms 1Solid Tumor 1Skin Diseases, Vascular 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pre-menopausal Breast Cancer 1

Interventions

Alpelisib 3Sirolimus 2mirdametinib 1Tablets 1Surgical Procedures, Operative 1Sildenafil Citrate 1Sclerotherapy 1Risk Factors 1Picibanil 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphangioma × Alpelisib × Clear all
NCT05948943 2026-06-02

EPIK-L1

Novartis

Phase 2/3 Recruiting
232 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT03941782 2024-01-11

Compassionate Use of BYL 719 Alpelisib

New Mexico Cancer Research Alliance

No longer available

Lymphangioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡